Table 1.
Patient characteristics at renal biopsy
| Characteristic | Total | Missing | |
|---|---|---|---|
| n = 119 | (%) | ||
| Age, years | 45 | (±16) | – |
| Sex, female, n (%) | 94 | (79) | – |
| Observation period, days | 2958 | (±2584) | – |
| SLEDAI-2 K score | 16 | (±6) | 53.8 |
| ISN/RPS classification | |||
| Class III, n (%) | 20 | (17) | – |
| Class III + V, n (%) | 2 | (10) | – |
| Class IV, n (%) | 84 | (71) | – |
| Class IV + V, n (%) | 7 | (8) | 0.8 |
| Class V, n (%) | 15 | (13) | – |
| Max dose of PSL, mg/day | 37 | (±15) | 5.0 |
| Immunosuppressive therapy for remission induction | 4.2 | ||
| PSL alone, n (%) | 46 | (39) | |
| Cyclophosphamide, n (%) | 31 | (26) | – |
| Tacrolimus or cyclosporine, n (%) | 22 | (19) | – |
| Mycophenolate mofetil, n (%) | 13 | (11) | – |
| Others, n (%) | 2 | (2) | – |
| Serum creatinine, mg/dl | 0.87 | (±0.51) | – |
| eGFR, ml/min/m2 | 77.3 | (±31.0) | – |
| Urinary protein, g/gCr | 3.00 | (±2.78) | – |
| Hematuria (scale > 2+), n (%) | 52 | (44) | 2.5 |
| Active urinary sediment, n (%) | 77 | (65) | 4.2 |
Data are presented as the mean and standard deviation in brackets. SLEDAI-2 K Systemic Lupus Erythematosus Disease Activity Index 2000; ISN/RPS International Society of Nephrology/Renal Pathology Society; PSL Prednisolone; eGFR Estimated glomerular filtration rate